475 related articles for article (PubMed ID: 25580592)
1. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.
Fleisher AS; Chen K; Quiroz YT; Jakimovich LJ; Gutierrez Gomez M; Langois CM; Langbaum JB; Roontiva A; Thiyyagura P; Lee W; Ayutyanont N; Lopez L; Moreno S; Muñoz C; Tirado V; Acosta-Baena N; Fagan AM; Giraldo M; Garcia G; Huentelman MJ; Tariot PN; Lopera F; Reiman EM
JAMA Neurol; 2015 Mar; 72(3):316-24. PubMed ID: 25580592
[TBL] [Abstract][Full Text] [Related]
2. Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study.
Quiroz YT; Schultz AP; Chen K; Protas HD; Brickhouse M; Fleisher AS; Langbaum JB; Thiyyagura P; Fagan AM; Shah AR; Muniz M; Arboleda-Velasquez JF; Munoz C; Garcia G; Acosta-Baena N; Giraldo M; Tirado V; Ramírez DL; Tariot PN; Dickerson BC; Sperling RA; Lopera F; Reiman EM
JAMA Neurol; 2015 Aug; 72(8):912-9. PubMed ID: 26121081
[TBL] [Abstract][Full Text] [Related]
3. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA
JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558
[TBL] [Abstract][Full Text] [Related]
4. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study.
Reiman EM; Quiroz YT; Fleisher AS; Chen K; Velez-Pardo C; Jimenez-Del-Rio M; Fagan AM; Shah AR; Alvarez S; Arbelaez A; Giraldo M; Acosta-Baena N; Sperling RA; Dickerson B; Stern CE; Tirado V; Munoz C; Reiman RA; Huentelman MJ; Alexander GE; Langbaum JB; Kosik KS; Tariot PN; Lopera F
Lancet Neurol; 2012 Dec; 11(12):1048-56. PubMed ID: 23137948
[TBL] [Abstract][Full Text] [Related]
5. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
[TBL] [Abstract][Full Text] [Related]
6. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.
Fleisher AS; Chen K; Quiroz YT; Jakimovich LJ; Gomez MG; Langois CM; Langbaum JB; Ayutyanont N; Roontiva A; Thiyyagura P; Lee W; Mo H; Lopez L; Moreno S; Acosta-Baena N; Giraldo M; Garcia G; Reiman RA; Huentelman MJ; Kosik KS; Tariot PN; Lopera F; Reiman EM
Lancet Neurol; 2012 Dec; 11(12):1057-65. PubMed ID: 23137949
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
[TBL] [Abstract][Full Text] [Related]
8. Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred.
Fuller JT; Cronin-Golomb A; Gatchel JR; Norton DJ; Guzmán-Vélez E; Jacobs HIL; Hanseeuw B; Pardilla-Delgado E; Artola A; Baena A; Bocanegra Y; Kosik KS; Chen K; Tariot PN; Johnson K; Sperling RA; Reiman EM; Lopera F; Quiroz YT
J Prev Alzheimers Dis; 2019; 6(2):112-120. PubMed ID: 30756118
[TBL] [Abstract][Full Text] [Related]
9. Retinal Imaging Findings in Carriers With PSEN1-Associated Early-Onset Familial Alzheimer Disease Before Onset of Cognitive Symptoms.
Armstrong GW; Kim LA; Vingopoulos F; Park JY; Garg I; Kasetty M; Silverman RF; Zeng R; Douglas VP; Lopera F; Baena A; Giraldo M; Norton D; Cronin-Golomb A; Arboleda-Velasquez JF; Quiroz YT; Miller JB
JAMA Ophthalmol; 2021 Jan; 139(1):49-56. PubMed ID: 33180114
[TBL] [Abstract][Full Text] [Related]
10. Association of Apolipoprotein E ɛ4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome.
Bejanin A; Iulita MF; Vilaplana E; Carmona-Iragui M; Benejam B; Videla L; Barroeta I; Fernandez S; Altuna M; Pegueroles J; Montal V; Valldeneu S; Giménez S; González-Ortiz S; Muñoz L; Padilla C; Aranha MR; Estellés T; Illán-Gala I; Belbin O; Camacho V; Wilson LR; Annus T; Osorio RS; Videla S; Lehmann S; Holland AJ; Zetterberg H; Blennow K; Alcolea D; Clarimon J; Zaman SH; Blesa R; Lleó A; Fortea J
JAMA Neurol; 2021 Aug; 78(8):937-947. PubMed ID: 34228042
[TBL] [Abstract][Full Text] [Related]
11. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
[TBL] [Abstract][Full Text] [Related]
12. PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriers.
Ghisays V; Lopera F; Goradia DD; Protas HD; Malek-Ahmadi MH; Chen Y; Devadas V; Luo J; Lee W; Baena A; Bocanegra Y; Guzmán-Vélez E; Pardilla-Delgado E; Vila-Castelar C; Fox-Fuller JT; Hu N; Clayton D; Thomas RG; Alvarez S; Espinosa A; Acosta-Baena N; Giraldo MM; Rios-Romenets S; Langbaum JB; Chen K; Su Y; Tariot PN; Quiroz YT; Reiman EM;
Neuroimage Clin; 2021; 31():102749. PubMed ID: 34252876
[TBL] [Abstract][Full Text] [Related]
13. PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers.
Balasa M; Vidal-Piñeiro D; Lladó A; Antonell A; Bosch B; Castellanos F; Bargalló N; Bartres-Faz D; Molinuevo JL; Sánchez-Valle R
J Alzheimers Dis; 2012; 30(3):605-16. PubMed ID: 22426017
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.
Morris JC; Schindler SE; McCue LM; Moulder KL; Benzinger TLS; Cruchaga C; Fagan AM; Grant E; Gordon BA; Holtzman DM; Xiong C
JAMA Neurol; 2019 Mar; 76(3):264-273. PubMed ID: 30615028
[TBL] [Abstract][Full Text] [Related]
15. White matter hyperintensities are a prominent feature of autosomal dominant Alzheimer's disease that emerge prior to dementia.
Schoemaker D; Zanon Zotin MC; Chen K; Igwe KC; Vila-Castelar C; Martinez J; Baena A; Fox-Fuller JT; Lopera F; Reiman EM; Brickman AM; Quiroz YT
Alzheimers Res Ther; 2022 Jun; 14(1):89. PubMed ID: 35768838
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
17. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
Therriault J; Vermeiren M; Servaes S; Tissot C; Ashton NJ; Benedet AL; Karikari TK; Lantero-Rodriguez J; Brum WS; Lussier FZ; Bezgin G; Stevenson J; Rahmouni N; Kunach P; Wang YT; Fernandez-Arias J; Socualaya KQ; Macedo AC; Ferrari-Souza JP; Ferreira PCL; Bellaver B; Leffa DT; Zimmer ER; Vitali P; Soucy JP; Triana-Baltzer G; Kolb HC; Pascoal TA; Saha-Chaudhuri P; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
JAMA Neurol; 2023 Feb; 80(2):188-199. PubMed ID: 36508198
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.
McDade E; Wang G; Gordon BA; Hassenstab J; Benzinger TLS; Buckles V; Fagan AM; Holtzman DM; Cairns NJ; Goate AM; Marcus DS; Morris JC; Paumier K; Xiong C; Allegri R; Berman SB; Klunk W; Noble J; Ringman J; Ghetti B; Farlow M; Sperling RA; Chhatwal J; Salloway S; Graff-Radford NR; Schofield PR; Masters C; Rossor MN; Fox NC; Levin J; Jucker M; Bateman RJ;
Neurology; 2018 Oct; 91(14):e1295-e1306. PubMed ID: 30217935
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
Palmqvist S; Zetterberg H; Blennow K; Vestberg S; Andreasson U; Brooks DJ; Owenius R; Hägerström D; Wollmer P; Minthon L; Hansson O
JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
[TBL] [Abstract][Full Text] [Related]
20. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM
JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
